SUPN Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Supernus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.12 |
| 52 Week High | US$39.37 |
| 52 Week Low | US$25.53 |
| Beta | 0.87 |
| 11 Month Change | 7.28% |
| 3 Month Change | 4.88% |
| 1 Year Change | 31.78% |
| 33 Year Change | 13.09% |
| 5 Year Change | 59.40% |
| Change since IPO | 572.63% |
Recent News & Updates
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Nov 12Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
Oct 31
Recent updates
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Nov 12Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
Oct 31Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
Sep 12Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings
Aug 19Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Jul 02Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
Apr 24Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Mar 04We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well
Oct 19Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment
Oct 10Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio
Aug 19Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear
Aug 16Supernus: A Work In Progress
Jul 29Supernus: New Beginnings
Mar 28Shareholder Returns
| SUPN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.4% | -3.8% | -1.0% |
| 1Y | 31.8% | 9.8% | 30.3% |
Return vs Industry: SUPN exceeded the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: SUPN exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| SUPN volatility | |
|---|---|
| SUPN Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SUPN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SUPN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 652 | Jack Khattar | www.supernus.com |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.
Supernus Pharmaceuticals, Inc. Fundamentals Summary
| SUPN fundamental statistics | |
|---|---|
| Market cap | US$1.96b |
| Earnings (TTM) | US$59.71m |
| Revenue (TTM) | US$651.97m |
33.4x
P/E Ratio3.1x
P/S RatioIs SUPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUPN income statement (TTM) | |
|---|---|
| Revenue | US$651.97m |
| Cost of Revenue | US$71.44m |
| Gross Profit | US$580.54m |
| Other Expenses | US$520.83m |
| Earnings | US$59.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.08 |
| Gross Margin | 89.04% |
| Net Profit Margin | 9.16% |
| Debt/Equity Ratio | 0% |
How did SUPN perform over the long term?
See historical performance and comparison